Content deleted Content added
Ozzie10aaaa (talk | contribs) |
Citation bot (talk | contribs) Added doi-access. | Use this bot. Report bugs. | Suggested by Лисан аль-Гаиб | #UCB_webform 202/279 |
||
(10 intermediate revisions by 7 users not shown) | |||
Line 1:
{{
{{Automatic taxobox
| image = Acinetobacter baumannii.JPG
| image_caption = ''Acinetobacter baumannii''
Line 78:
}}
'''''Acinetobacter''''' is a [[genus]] of [[
They are important [[soil life|soil organisms]], where they contribute to the [[Mineralization (soil)|mineralization]] of, for example, [[Aromaticity|aromatic compounds]]. ''Acinetobacter'' species are a key source of infection in debilitated patients in the hospital, in particular the species ''[[Acinetobacter baumannii]]''.
==Description==
Species of the genus ''Acinetobacter'' are [[Aerobic organism|strictly aerobic]], [[Fermentation (biochemistry)|nonfermentative]], [[Gram-negative]] [[Bacteria#Morphology|bacilli]]. They show mostly a [[Coccobacillus|coccobacillary]] morphology on nonselective agar. Rods predominate in fluid media, especially during early growth.{{
The morphology of ''Acinetobacter'' species can be quite variable in Gram-stained human clinical specimens, and cannot be used to differentiate ''Acinetobacter'' from other common causes of infection.{{
Most strains of ''Acinetobacter'', except some of the ''A. lwoffii'' strain, grow well on [[MacConkey agar]] (without salt). Although officially classified as not lactose-fermenting, they are often partially lactose-fermenting when grown on MacConkey agar. They are [[oxidase]]-negative, catalase-positive, indole-negative, [[motility|nonmotile]], and usually [[nitrate]]-negative.{{
Bacteria of the genus ''Acinetobacter'' are known to form intracellular inclusions of [[polyhydroxyalkanoates]] under certain environmental conditions (e.g. lack of elements such as phosphorus, nitrogen, or oxygen combined with an excessive supply of carbon sources).{{
== Etymology ==
''Acinetobacter'' is a compound word from scientific Greek [α + κίνητο + βακτηρ(ία)], meaning nonmotile rod. The first element ''acineto-'' appears as a somewhat [[baroque]] rendering of the Greek [[morpheme]] ακίνητο-, commonly [[transliteration|transliterated]] in English is ''akineto-'', but actually stems from the French ''cinetique'' and was adopted directly into English.{{
==Taxonomy==
The genus ''Acinetobacter'' comprises 38 validly named species.<ref name=Visca2011>{{cite journal |vauthors=Visca P, Seifert H, Towner KJ |title=Acinetobacter infection--an emerging threat to human health |journal=IUBMB Life |volume=63 |issue=12 |pages=1048–54 |date=December 2011 |pmid=22006724 |doi=10.1002/iub.534 |s2cid=45593914 |doi-access=free }}</ref>
== Identification ==
Identification of ''Acinetobacter'' species is complicated by lack of standard identification techniques. Initially, identification was based on phenotypic characteristics such as growth temperature, [[colony morphology]], growth medium, carbon sources, gelatin hydrolysis, glucose fermentation, among others. This method allowed identification of ''A. calcoaceticus–A. baumannii'' complex by the formation of smooth, rounded, mucoid colonies at 37 °C. Closely related species could not be differentiated and individual species such as ''A. baumannii'' and ''Acinetobacter'' genomic species 3 could not be positively identified phenotypically.{{
Because routine identification in the clinical microbiology laboratory is not yet possible, ''Acinetobacter'' isolates are divided and grouped into three main complexes:{{
* ''Acinetobacter calcoaceticus-baumannii complex'': glucose-oxidising nonhemolytic (''A. baumannii'' can be identified by OXA-51 typing)
* ''Acinetobacter lwoffii'': glucose-negative nonhemolytic
Line 114:
==Clinical significance==
<!--Intro concerning all Acinetobacter-->
''Acinetobacter'' is frequently isolated in [[nosocomial infection]]s, and is especially prevalent in [[intensive care unit]]s, where both sporadic cases and [[epidemic]] and [[Endemic (epidemiology)|endemic]] occurrences are common. ''A. baumannii'' is a frequent cause of [[Pneumonia#Hospital-acquired|hospital-acquired pneumonia]], especially of late-onset, [[ventilator-associated pneumonia]]. It can cause various other infections, including skin and wound infections, [[bacteremia]], and [[meningitis]], but ''A. lwoffi'' is mostly responsible for the latter.{{
<!-- A. baumannii disease -->
Of the ''Acinetobacter'', ''A. baumannii'' is the greatest cause of human disease, having been implicated in a number of hospital-acquired infections such as bacteremia, urinary tract infections (UTIs), secondary meningitis, infective endocarditis, and wound and burn infections.<ref>{{cite journal | last1 = Dent Lemuel | first1 = L | last2 = Marshall | first2 = DR | last3 = Pratap | first3 = S | last4 = Hulette | first4 = RB | year = 2010 | title = Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital | journal = BMC Infect Dis | volume = 10 | page = 196 | doi=10.1186/1471-2334-10-196| pmid = 20609238 | pmc = 2909240 | doi-access = free }}</ref> In particular, ''A. baumannii'' is frequently isolated as the cause of hospital-acquired pneumonia among patients admitted to the [[intensive care unit]]. Risk factors include long-term intubation and tracheal or lung aspiration. In most cases of ventilator-associated pneumonia, the equipment used for artificial ventilation such as endotracheal tubes or bronchoscopes serve as the source of infection and result in the colonization of the lower respiratory tract by ''A. baumannii''. In some cases, the bacteria can go on to enter the bloodstream, resulting in bacteremia with mortality rates ranging from 32% to 52%. UTIs caused by ''A. baumannii'' appear to be associated with continuous catheterization, as well as antibiotic therapy. ''A. baumannii'' has also been reported to infect skin and soft tissue in traumatic injuries and postsurgical wounds. ''A. baumannii'' commonly infect burns and may result in complications owing to difficulty in treatment and eradication. Though less common, some evidence also links this bacterium to meningitis, most often following invasive surgery, and, in very rare cases, to community-acquired primary meningitis wherein the majority of the victims were children.<ref>{{cite journal | last1 = Siegman-Igra | first1 = Y | last2 = Bar-Yosef | first2 = S | last3 = Gorea | first3 = A | last4 = Avram | first4 = J | year = 1993 | title = Nosocomial Acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review | journal = Clin Infect Dis | volume = 17 | issue = 5| pages = 843–849 | doi=10.1093/clinids/17.5.843| pmid = 8286623 }}</ref> Case reports also link ''A. baumannii'' to endocarditis, keratitis, peritonitis, and very rarely fatal neonatal sepsis.<ref>{{cite journal | last1 = Falagas | first1 = ME | last2 = Karveli | first2 = EA | last3 = Kelesidis | first3 = I | last4 = Kelesidis | first4 = T | year = 2007 | title = Community acquired Acinetobacter infections | journal = Eur J Clin Microbiol Infect Dis | volume = 26 | issue = 12| pages = 857–868 | doi=10.1007/s10096-007-0365-6| pmid = 17701432 | s2cid = 25898468 }}</ref>
<!-- A. baumannii resistance/resilience -->
The clinical significance of ''A. baumannii'' is partially due to its capacity to develop resistance against many available antibiotics. Reports indicate that it possesses resistance against broad-spectrum [[cephalosporin]]s, [[β-lactam antibiotic]]s, [[aminoglycosides]], and [[quinolones]]. Resistance to [[carbapenem]]s is also being increasingly reported.<ref>{{cite journal | last1 = Hu | first1 = Q | last2 = Hu | first2 = Z | last3 = Li | first3 = J | last4 = Tian | first4 = B | last5 = Xu | first5 = H | last6 = Li | first6 = J | year = 2011 | title = Detection of OXA-type carbapenemases and integrons among carbapenem-resistant Acinetobactor baumannii in a Teaching Hospital in China | journal = J Basic Microbiol | volume = 51 | issue = 5| pages = 467–472 | doi=10.1002/jobm.201000402| pmid = 21656808 | s2cid = 10955468 | doi-access = free }}</ref><ref>{{cite journal | first1 = Pierre Edouard | last1 = Fournier | last2 = Richet | first2 = H | year = 2006 | title = The epidemiology and control of Acinetobacter baumannii in healthcare facilities | doi =10.1086/500202 | pmid = 16447117 | journal = Clin Infect Dis | volume = 42 | issue = 5| pages = 692–699 | doi-access = free }}</ref> ''A. baumannii'' can survive on the human skin or dry surfaces for weeks and is resistant to a variety of disinfectants, making it particularly easy to spread in a hospital setting.<ref name=Peleg2008>{{cite journal|title=''Acinetobacter baumannii'': Emergence of a Successful Pathogen |author1=Peleg AY |author2=Seifert H |author3=Paterson DL |journal=Clinical Microbiology Reviews |date=July 2008 |volume=21 |issue=3 |pages=538–582 |pmc=2493088 |doi=10.1128/CMR.00058-07 |pmid=18625687}}</ref> Antibiotic resistance genes are often plasmid-borne, and plasmids present in ''Acinetobacter'' strains can be transferred to other pathogenic bacteria by [[horizontal gene transfer]].{{
<!-- Role in Allergy -->
Line 141:
== Treatment ==
''Acinetobacter'' species are innately resistant to many classes of antibiotics, including [[penicillin]], [[chloramphenicol]], and often [[aminoglycoside]]s. Resistance to [[fluoroquinolones]] has been reported during therapy, which has also resulted in increased resistance to other drug classes mediated through active drug [[efflux (microbiology)|efflux]]. A dramatic increase in [[antibiotic resistance]] in ''Acinetobacter'' strains has been reported by the [[Centers for Disease Control and Prevention]] (CDC), and the carbapenems are recognised as the gold-standard and treatment of last resort.<ref name=Rahal_2006>{{cite journal | author = Rahal J | title = Novel antibiotic combinations against infections with almost completely resistant ''Pseudomonas aeruginosa'' and ''Acinetobacter'' species | journal = Clin Infect Dis | volume = 43
In November 2004, the CDC reported an increasing number of ''A. baumannii'' bloodstream infections in patients at military medical facilities in which service members injured in the [[Iraq]]/[[Kuwait]] region during [[Operation Iraqi Freedom]] and in [[Afghanistan]] during [[Operation Enduring Freedom]] were treated.<ref name=MMWR_2004>{{cite journal | title = ''Acinetobacter baumannii'' infections among patients at military medical facilities treating injured U.S. service members, 2002-2004 | journal = MMWR Morb Mortal Wkly Rep | volume = 53 | issue = 45 | pages = 1063–6 | year = 2004|pmid = 15549020 | author1 = Centers for Disease Control and Prevention}}</ref> Most of these were multidrug-resistant. Among one set of isolates from [[Walter Reed Army Medical Center]], 13 (35%) were susceptible to [[imipenem]] only, and two (4%) were resistant to all drugs tested. One antimicrobial agent, [[colistin]] (polymyxin E), has been used to treat infections with multidrug-resistant ''A. baumannii''; however, antimicrobial susceptibility testing for colistin was not performed on isolates described in this report. Because ''A. baumannii'' can survive on dry surfaces up to 20 days, they pose a high risk of spread and contamination in hospitals, potentially putting immunocompromised and other patients at risk for drug-resistant infections that are often fatal and, in general, expensive to treat. Trials to implement vaccines to prevent Acinetobacter infections were documented.<ref name="Ahmad2016">{{cite journal |vauthors=Ahmad TA, Tawfik DM, Sheweita SA, Haroun M, El-Sayed LH| title=Development of immunization trials against Acinetobacter baumannii| journal=Trials in Vaccinology| year=2016 | volume=5 | pages=53–60 | doi=10.1016/j.trivac.2016.03.001| doi-access=free}}</ref><ref name="Tawfik2017">{{cite journal |vauthors=Tawfik DM, AhmadTA, Sheweita SA, Haroun M, El-Sayed LH| title=The detection of antigenic determinants of Acinetobacter baumannii| journal=Immunology Letters| year=2017 | volume=186 | pages=59–67 | doi=10.1016/j.imlet.2017.04.004| pmid=28427887|url=https://www.sciencedirect.com/science/article/pii/S0165247817300901}}</ref>
Line 148:
Gene-silencing antisense oligomers in a form called peptide-conjugated phosphorodiamidate [[morpholino]] oligomers have also been reported to inhibit growth in tests carried out in animals infected with antibiotic-resistant ''A. baumannii''.<ref name="Geller 2013">{{cite journal |vauthors=Geller BL, Marshall-Batty K, Schnell FJ |title=Gene-Silencing Antisense Oligomers Inhibit Acinetobacter Growth In Vitro and In Vivo. J. Infect. Diseases |date=October 2013|display-authors=etal}}</ref><ref name="OSU News">{{cite web |url=http://oregonstate.edu/ua/ncs/archives/2013/oct/beyond-antibiotics-%E2%80%9Cppmos%E2%80%9D-offer-new-approach-bacterial-infection |title=Beyond antibiotics: PPMOs offer new approach to bacterial infection |date=2013-10-15 |access-date=October 15, 2013 }}</ref>
[[Sulbactam/durlobactam]] (Xacduro) was approved for medical use in the United States in May 2023.<ref name="FDA PR 20230523">{{cite press release | title=FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria | website=U.S. Food and Drug Administration | date=24 May 2023 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria | access-date=24 May 2023}} {{PD-notice}}</ref>
==Aseptic technique==
Line 179 ⟶ 181:
{{Taxonbar|from=Q310457}}
{{Authority control}}
[[Category:Bacteria genera]]
|